nach oben

Erschienen in:

01.02.2012 | Original Article—Liver, Pancreas, and Biliary Tract

Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells

verfasst von: Shigeyuki Takeshita, Tatsuki Ichikawa, Naota Taura, Hisamitsu Miyaaki, Toshihisa Matsuzaki, Masashi Otani, Toru Muraoka, Motohisa Akiyama, Satoshi Miuma, Eisuke Ozawa, Masanori Ikeda, Nobuyuki Kato, Hajime Isomoto, Fuminao Takeshima, Kazuhiko Nakao

Erschienen in: Journal of Gastroenterology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Geranylgeranylacetone (GGA), an isoprenoid compound which includes retinoids, has been used orally as an anti-ulcer drug in Japan. GGA acts as a potent inducer of anti-viral gene expression by stimulating ISGF3 formation in human hepatoma cells. This drug has few side effects and reinforces the effect of IFN when administered in combination with peg-IFN and ribavirin. This study verified the anti-HCV activity of GGA in a replicon system. In addition, mechanisms of anti-HCV activity were examined in the replicon cells.

Methods

OR6 cells stably harboring the full-length genotype 1 replicon containing the Renilla luciferase gene, ORN/C-5B/KE, were used to examine the influence of the anti-HCV effect of GGA. After treatment, the cells were harvested with Renilla lysis reagent and then subjected to a luciferase assay according to the manufacturer’s protocol.

Result

The results showed that GGA had anti-HCV activity. GGA induced anti-HCV replicon activity in a time- and dose-dependent manner. GGA did not activate the tyrosine 701 and serine 727 on STAT-1, and did not induce HSP-70 in OR6 cells. The anti-HCV effect depended on the GGA induced mTOR activity, not STAT-1 activity and PKR. An additive effect was observed with a combination of IFN and GGA.

Conclusions

GGA has mTOR dependent anti-HCV activity. There is a possibility that the GGA anti-HCV activity can be complimented by IFN. It will be necessary to examine the clinical effectiveness of the combination of GGA and IFN for HCV patients in the future.

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.PubMedCrossRef

Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132:1979–98.PubMedCrossRef

Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T. Antiulcer effect of geranylgeranylacetone, a new acyclic polyisoprenoid, on experimentally induced gastric and duodenal ulcers in rats. Arzneimittelforschung. 1981;31:799–804.PubMed

Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Inai Y, Abe S, et al. Effect of synthetic acyclic polyisoprenoids on the cold-restraint stress induced gastric ulcer in rats. Jpn J Pharmacol. 1983;33:549–56.PubMedCrossRef

Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology. 1996;111:345–57.PubMedCrossRef

Sakai I, Tanaka T, Osawa S, Hashimoto S, Nakaya K. Geranylgeranylacetone used as an antiulcer agent is a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun. 1993;191:873–9.PubMedCrossRef

Okada S, Yabuki M, Kanno T, Hamazaki K, Yoshioka T, Yasuda T, et al. Geranylgeranylacetone induces apoptosis in HL-60 cells. Cell Struct Funct. 1999;24:161–8.PubMedCrossRef

Araki H, Shidoji Y, Yamada Y, Moriwaki H, Muto Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun. 1995;209:66–72.PubMedCrossRef

Kuhen KL, Vessey JW, Samuel CE. Mechanism of interferon action: identification of essential positions within the novel 15-base-pair KCS element required for transcriptional activation of the RNA-dependent protein kinase PKR gene. J Virol. 1998;72:9934–9.PubMed

10.

Ichikawa T, Nakao K, Nakata K, Hamasaki K, Takeda Y, Kajiya Y, et al. Geranylgeranylacetone induces antiviral gene expression in human hepatoma cells. Biochem Biophys Res Commun. 2001;280:933–9.PubMedCrossRef

11.

Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun. 2005;329:1350–9.PubMedCrossRef

12.

Tanaka H, Samuel CE. Mechanism of interferon action. Structure of the mouse PKR gene encoding the interferon-inducible RNA-dependent protein kinase. Proc Natl Acad Sci USA. 1994;91:7995–9.

13.

14.

Uchida S, Fujiki M, Nagai Y, Abe T, Kobayashi H. Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to neuroprotection against cerebral infarction in rats. Neurosci Lett. 2006;396:220–4.PubMedCrossRef

15.

Fujibayashi T, Hashimoto N, Jijiwa M, Hasegawa Y, Kojima T, Ishiguro N. Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model. BMC Pulm Med. 2009;9:45.PubMedCrossRef

16.

Sakabe M, Shiroshita-Takeshita A, Maguy A, Brundel BJ, Fujiki A, Inoue H, et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res. 2008;78:63–70.PubMedCrossRef

17.

Fudaba Y, Ohdan H, Tashiro H, Ito H, Fukuda Y, Dohi K, et al. Geranylgeranylacetone, a heat shock protein inducer, prevents primary graft nonfunction in rat liver transplantation. Transplantation. 2001;72:184–9.PubMedCrossRef

18.

Mochida S, Matsura T, Yamashita A, Horie S, Ohata S, Kusumoto C, et al. Geranylgeranylacetone ameliorates inflammatory response to lipopolysaccharide (LPS) in murine macrophages: inhibition of LPS binding to the cell surface. J Clin Biochem Nutr. 2007;41:115–23.PubMedCrossRef

19.

Kanemura H, Kusumoto K, Miyake H, Tashiro S, Rokutan K, Shimada M. Geranylgeranylacetone prevents acute liver damage after massive hepatectomy in rats through suppression of a CXC chemokine GRO1 and induction of heat shock proteins. J Gastrointest Surg. 2009;13:66–73.PubMedCrossRef

20.

Hirota K, Nakamura H, Arai T, Ishii H, Bai J, Itoh T, et al. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun. 2000;275:825–30.PubMedCrossRef

21.

Schenk H, Klein M, Erdbrügger W, Dröge W, Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci USA. 1994;91:1672–6.PubMedCrossRef

22.

Unoshima M, Iwasaka H, Eto J, Takita-Sonoda Y, Noguchi T, Nishizono A. Antiviral effects of geranylgeranylacetone: enhancement of MxA expression and phosphorylation of PKR during influenza virus infection. Antimicrob Agents Chemother. 2003;47:2914–21.PubMedCrossRef

23.

Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology. 2005;128:1034–41.PubMedCrossRef

24.

Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, et al. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J Hepatol. 2007;46:759–67.PubMedCrossRef

25.

Luquin E, Larrea E, Civeira MP, Prieto J, Aldabe R. HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway. Antiviral Res. 2007;76:194–7.PubMedCrossRef

26.

Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology. 2007;132:733–44.PubMedCrossRef

27.

Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology. 2004;126:263–77.PubMedCrossRef

28.

Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia. 2005;19:209–13.PubMedCrossRef

29.

Jia Y, Wei L, Jiang D, Wang J, Cong X, Fei R. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8. J Gastroenterol Hepatol. 2007;22:1278–85.PubMedCrossRef

30.

Fredericksen B, Akkaraju GR, Foy E, Wang C, Pflugheber J, Chen ZJ, et al. Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol. 2002;15:29–40.PubMedCrossRef

31.

Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimito M, et al. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol. 2009;44:856–63.PubMedCrossRef

32.

Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker DP, et al. Regulatory effects of mammalian target of rapamycin activated pathways in type I and II interferon signaling. J Biol Chem. 2007;282:1757–68.PubMedCrossRef

33.

Ishida H, Li K, Yi M, Lemon SM. p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem. 2007;282:11836–48.PubMedCrossRef

34.

Hasegawa J, Morishita N, Seki T, Hashida N, Kanazawa T, Sato A. Effect of meals in healthy adult administered Selbex. Syokakika. 1987;7:740–52.

Titel: Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells
verfasst von: Shigeyuki Takeshita
Tatsuki Ichikawa
Naota Taura
Hisamitsu Miyaaki
Toshihisa Matsuzaki
Masashi Otani
Toru Muraoka
Motohisa Akiyama
Satoshi Miuma
Eisuke Ozawa
Masanori Ikeda
Nobuyuki Kato
Hajime Isomoto
Fuminao Takeshima
Kazuhiko Nakao
Publikationsdatum: 01.02.2012
Verlag: Springer Japan
Erschienen in: Journal of Gastroenterology / Ausgabe 2/2012
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-011-0481-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Result

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

Comparisons of symptoms reported by elderly and non-elderly patients with GERD

Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients

Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease